论文部分内容阅读
促红细胞生成素(EPO)能直接促进红细胞生成,可用于预防和治疗多种原因引起的贫血。EPO广泛分布于人体各个系统,除促造血作用外,还具有抗炎、抗凋亡、促进新生血管生成等多种作用,并可通过这些作用发挥广泛的组织保护效能。然而,长期大剂量应用EPO必然增加高血压、血栓形成等风险。氨甲酰化促红细胞生成素(carbamylated erythropoietin,CEPO)作为EPO衍生物的代表,不仅药代动力学特征与EPO相似,且可通过抗炎、抗凋亡、促进新生血管生成等多种作用减轻心、脑、肾等器官的缺血-再灌注损伤,但其无促红细胞生成活性,不会增加高血压及血栓形成风险。因此,CEPO的应用前景比EPO更为广阔。该文将EPO及CEPO的心脏保护作用作一综述。
Erythropoietin (EPO) can directly promote erythropoiesis, can be used to prevent and treat a variety of causes of anemia. EPO widely distributed in various systems in the body, in addition to promote hematopoietic function, but also has anti-inflammatory, anti-apoptotic, and promote angiogenesis and many other roles, and can play a wide range of tissue protection through these effects. However, long-term high-dose EPO inevitably increases the risk of hypertension and thrombosis. As a representative of EPO derivatives, carbamylated erythropoietin (CEPO) not only has pharmacokinetic characteristics similar to those of EPO, but also can be relieved by various actions such as anti-inflammation, anti-apoptosis and angiogenesis promotion Heart, brain, kidney and other organs of ischemia-reperfusion injury, but no erythropoietic activity, will not increase the risk of hypertension and thrombosis. Therefore, the application prospect of CEPO is broader than EPO. This article reviews the cardioprotective effects of EPO and CEPO.